Target Price | $11.14 |
Price | $9.52 |
Potential |
17.05%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Adaptive Biotechnologies Corp 2026 .
The average Adaptive Biotechnologies Corp target price is $11.14.
This is
17.05%
register free of charge
$13.00
36.55%
register free of charge
$9.00
5.46%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend Adaptive Biotechnologies Corp to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Adaptive Biotechnologies Corp stock has an average upside potential 2026 of
17.05%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 178.96 | 219.26 |
5.10% | 22.52% | |
EBITDA Margin | -81.03% | -21.14% |
26.38% | 73.91% | |
Net Margin | -89.12% | -59.36% |
32.63% | 33.39% |
8 Analysts have issued a sales forecast Adaptive Biotechnologies Corp 2025 . The average Adaptive Biotechnologies Corp sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Adaptive Biotechnologies Corp EBITDA forecast 2025. The average Adaptive Biotechnologies Corp EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Adaptive Biotechnologies Corp Analysts have issued a net profit forecast 2025. The average Adaptive Biotechnologies Corp net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.08 | -0.86 |
30.77% | 20.37% | |
P/E | negative | |
EV/Sales | 6.32 |
3 Analysts have issued a Adaptive Biotechnologies Corp forecast for earnings per share. The average Adaptive Biotechnologies Corp EPS is
This results in the following potential growth metrics and future valuations:
Adaptive Biotechnologies Corp...
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Locked
➜
Locked
|
Locked | May 06 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | May 05 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | May 02 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
Analyst Rating | Date |
---|---|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 06 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 05 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 02 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 21 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 13 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jan 28 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.